Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Budesonide

FDA-approved product (aerosol, metered, nasal), marketed as Budesonide, Entocort Ec, Eohilia and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Budesonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Crohn's disease
  • Emphysema
  • Esophageal disease
  • IGA glomerulonephritis
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids acting locally; Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Budesonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Budesonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)

    NCT07318350 · start 2026-10

    Registered record
    Registry ID
    NCT07318350
    Conditions
    Moderate Asthma
    Interventions
    N0783; Alenia® (Formoterol 6 mcg / Budesonide 200 mcg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-09
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Asthma
    InterventionN0783; Alenia® (Formoterol 6 mcg / Budesonide 200 mcg)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months

    NCT07675252 · start 2026-08-01

    Registered record
    Registry ID
    NCT07675252
    Conditions
    Acute Wheezing Disorders in Infants Aged 0 to 24 Months
    Interventions
    Fluticasone Propionate Nebulization; Budesonide Nebulization
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2027-06-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Wheezing Disorders in Infants Aged 0 to 24 Months
    InterventionFluticasone Propionate Nebulization; Budesonide Nebulization
    PhasePhase 4
    Registry statusNot yet recruiting

  • Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study)

    NCT07684105 · start 2026-07-01

    Registered record
    Registry ID
    NCT07684105
    Conditions
    Recessive Dystrophic Epidermolysis Bullosa; Dysphagia; Esophageal Stenosis
    Interventions
    The retrospective data collected will be entered into an eCRF and then analyzed centrally
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-06-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecessive Dystrophic Epidermolysis Bullosa; Dysphagia; Esophageal Stenosis
    InterventionThe retrospective data collected will be entered into an eCRF and then analyzed centrally
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

    NCT07807007 · start 2025-11-21

    Registered record
    Registry ID
    NCT07807007
    Conditions
    Asthma
    Interventions
    Budesonide, Formoterol Fumarate, and Umeclidinium Bromide; Budesonide, Formoterol Fumarate, and Umeclidinium Bromide; Budesonide and Formoterol Fumarate; Placebo for CP006 Inhalation Powder; Placebo for Budesonide and Formoterol Fumarate; Albuterol Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-11-21
    Completion
    2026-08-17
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBudesonide, Formoterol Fumarate, and Umeclidinium Bromide; Budesonide, Formoterol Fumarate, and Umeclidinium Bromide; Budesonide and Formoterol Fumarate; Placebo for CP006 Inhalation Powder +2 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma

    NCT06940700 · start 2025-04

    Registered record
    Registry ID
    NCT06940700
    Conditions
    Asthma
    Interventions
    SHR4597; Budesonide inhalant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-04
    Completion
    2025-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionSHR4597; Budesonide inhalant
    PhasePhase 2
    Registry statusNot yet recruiting

  • The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis

    NCT06756243 · start 2025-03-01

    Registered record
    Registry ID
    NCT06756243
    Conditions
    Allergic Rhinitis
    Interventions
    Hydrogen Ion Water（Shan Shang Water）; Budesonide Nasal Spray therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-03-01
    Completion
    2026-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionHydrogen Ion Water（Shan Shang Water）; Budesonide Nasal Spray therapy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Pharmacokinetics and Bioequivalence Study of Budesonide Inhalation Aerosol in Humans

    NCT06924190 · start 2024-12-30

    Registered record
    Registry ID
    NCT06924190
    Conditions
    Bioequivalence Study in Healthy Subjects
    Interventions
    Budiair® 200ug/puff inhalation aerosol; budesonide 200ug/puff inhalation aerosol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-12-30
    Completion
    2025-01-20
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence Study in Healthy Subjects
    InterventionBudiair® 200ug/puff inhalation aerosol; budesonide 200ug/puff inhalation aerosol
    PhaseNot applicable
    Registry statusCompleted

  • A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

    NCT06676007 · start 2024-10-30

    Registered record
    Registry ID
    NCT06676007
    Conditions
    IgA Nephropathy (IgAN); Early Initial Therapy
    Interventions
    Gd-IgA1 test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-10-30
    Completion
    2027-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIgA Nephropathy (IgAN); Early Initial Therapy
    InterventionGd-IgA1 test
    PhaseNot recorded
    Registry statusRecruiting

  • Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

    NCT06590740 · start 2024-10-18

    Registered record
    Registry ID
    NCT06590740
    Conditions
    Cough-Variant Asthma
    Interventions
    Budesonide-Formoterol treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-10-18
    Completion
    2025-09-03
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCough-Variant Asthma
    InterventionBudesonide-Formoterol treatment
    PhasePhase 4
    Registry statusCompleted

  • A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

    NCT06471257 · start 2024-06-17

    Registered record
    Registry ID
    NCT06471257
    Conditions
    Asthma
    Interventions
    Budesonide/Albuterol metered dose inhaler, MDI; Albuterol sulfate metered dose inhaler, MDI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-06-17
    Completion
    2027-10-04
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBudesonide/Albuterol metered dose inhaler, MDI; Albuterol sulfate metered dose inhaler, MDI
    PhasePhase 3
    Registry statusRecruiting

  • Budesonide as a Treatment for Functional Dyspepsia

    NCT06841406 · start 2024-05-01

    Registered record
    Registry ID
    NCT06841406
    Conditions
    Functional Dyspepsia
    Interventions
    budesonide; Mannitol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-05-01
    Completion
    2026-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFunctional Dyspepsia
    Interventionbudesonide; Mannitol
    PhasePhase 4
    Registry statusRecruiting

  • Combination of Diet and Oral Budesonide for Ulcerative Colitis

    NCT05791487 · start 2023-12-01

    Registered record
    Registry ID
    NCT05791487
    Conditions
    Ulcerative Colitis; Ulcerative Colitis Chronic Mild; Ulcerative Colitis Chronic Moderate
    Interventions
    Ulcerative colitis Exclusion Diet; Partial enteral nutrition (PEN); free diet; Oral Budesonide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-12-01
    Completion
    2026-09-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis; Ulcerative Colitis Chronic Mild; Ulcerative Colitis Chronic Moderate
    InterventionUlcerative colitis Exclusion Diet; Partial enteral nutrition (PEN); free diet; Oral Budesonide
    PhaseNot applicable
    Registry statusUnknown

  • Dupilumab in Chinese Adult Participants With CRSwNP

    NCT05878093 · start 2023-05-16

    Registered record
    Registry ID
    NCT05878093
    Conditions
    Chronic Rhinosinusitis With Nasal Polyps
    Interventions
    Dupilumab; Placebo; Budesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-16
    Completion
    2024-11-28
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis With Nasal Polyps
    InterventionDupilumab; Placebo; Budesonide
    PhasePhase 3
    Registry statusCompleted

  • PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

    NCT05555290 · start 2022-09-28

    Registered record
    Registry ID
    NCT05555290
    Conditions
    Asthma
    Interventions
    PT027; PT007
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-09-28
    Completion
    2024-11-18
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionPT027; PT007
    PhasePhase 3
    Registry statusCompleted

  • 3TR Asthma Biologics Cohort (ABC) Study

    NCT06126692 · start 2022-01-10

    Registered record
    Registry ID
    NCT06126692
    Conditions
    Severe Asthma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-01-10
    Completion
    2033-08
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Asthma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting